News | January 05, 2023
Biocytogen and Hansoh Pharma announce an antibody license agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
To create leading company developing medicines targeting metalloenzymes
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
LG Chem will receive totaling up to $95.5 million for the China rights
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Roy is the right successor to lead Philips’ efforts to help improve the health and well-being of people globally
Subscribe To Our Newsletter & Stay Updated
